Screener

Revenue from Contract with Customer, Excluding Assessed Tax

Jazz Pharmaceuticals·Products & Services·17 segments·Rolls up to Total Revenue

Breakdown

Segment	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Xywav	$368.47M	$388.47M	$400.96M	$344.8M	$415.32M	$431.41M	$465.45M	$408.2M
Epidiolex/Epidyolex	$247.1M	$251.56M	$275.05M	$217.7M	$251.73M	$302.61M	$287.12M	$249.8M
Rylaze/Enrylaze	$107.83M	$98.78M	$101.49M	$94.2M	$100.66M	$99.87M	$108.16M	$103.7M
Zepzelca	$81.05M	$85.84M	$78.33M	$63M	$74.54M	$79.3M	$90.44M	$101M
Defitelio/defibrotide	$45.42M	$65.82M	$57.65M	$40.7M	$48.11M	$51.75M	$58.87M	$47.4M
Modeyso	—	$0	$0	$0	$470K	$11.03M	$36.54M	$41.4M
High-sodium oxybate AG royalty revenue	$54.16M	$58.16M	$55.31M	$48.9M	$54.14M	$52.95M	$55.7M	$36.3M
Xyrem	$62.18M	$58.11M	$49.29M	$37.2M	$35.35M	$35.66M	$37.78M	$31.2M
Vyxeos	$43.01M	$34.31M	$53.25M	$29.5M	$44.85M	$37.58M	$34.73M	$26.6M
Ziihera	—	—	—	$2M	$5.99M	$8.31M	$8.54M	$13.3M
Other royalty and contract revenues	$5.52M	$7.11M	—	$9.5M	$6M	$8.75M	—	$7.3M
Other	$2.7M	$2.23M	$2.97M	$10.3M	$4.41M	$2.14M	$3.31M	$2.7M
Total	$1.02B	$1.05B	$1.09B	$897.8M	$1.05B	$1.13B	$1.2B	$1.07B